Trial Profile
Phase II Study of a Proteasome Inhibitor, PS-341 (NSC 681239) in Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 12 Nov 2018 Status changed from completed to discontinued.
- 24 Oct 2012 New trial record